RxDoctor Payments Data

Sailaja Seethamraju, DO

Internal Medicine · Dallas, TXNPI 1861788549

Payments from drug & device makers

$862in general payments, 2019–2025

Across 45 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$227
  • AstraZeneca$150
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$123
  • Axsome Therapeutics, Inc.$87
  • Lilly USA, LLC$60
  • Novo Nordisk$44
  • plus $171 from 7 others

What the payments were for

  • Food & beverage$862100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$862 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$83,042
Medicare patients
62
Services billed
775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$38,746
OzempicSemaglutide11$11,415
LinzessLinaclotide17$9,855
EntrestoSacubitril/Valsartan26$8,862
GemtesaVibegron35$8,461
MyrbetriqMirabegron28$6,544
FarxigaDapagliflozin Propanediol21$6,142
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$5,975
Potassium Chloride111$3,301
Budesonide25$3,096
Duloxetine Hcl34$2,121
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$1,999
Gabapentin147$1,791
Ranolazine ErRanolazine11$1,295
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate29$1,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$44$11,41511 claims
AbbVieLinzess$227$9,85517 claims
Astellas Pharma US IncMyrbetriq$16$6,54428 claims
AstraZenecaFarxiga$150$6,14221 claims
GSKTrelegy Ellipta$18$5,97512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →